Last reviewed · How we verify
Relugolix 120 MG [Orgovyx] — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Relugolix 120 MG [Orgovyx] (relugolix-120-mg-orgovyx) — Pfizer Inc.. Relugolix binds to and inhibits the gonadotropin-releasing hormone (GnRH) receptor, reducing the production of luteinizing hormone and follicle-stimulating hormone.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Relugolix 120 MG [Orgovyx] TARGET | relugolix-120-mg-orgovyx | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Relugolix 120 MG [Orgovyx] CI watch — RSS
- Relugolix 120 MG [Orgovyx] CI watch — Atom
- Relugolix 120 MG [Orgovyx] CI watch — JSON
- Relugolix 120 MG [Orgovyx] alone — RSS
Cite this brief
Drug Landscape (2026). Relugolix 120 MG [Orgovyx] — Competitive Intelligence Brief. https://druglandscape.com/ci/relugolix-120-mg-orgovyx. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab